Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:BSTC's Cash to Debt is ranked higher than
100% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. NAS:BSTC: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:BSTC' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.85
NAS:BSTC's Equity to Asset is ranked higher than
74% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:BSTC: 0.85 )
Ranked among companies with meaningful Equity to Asset only.
NAS:BSTC' s Equity to Asset Range Over the Past 10 Years
Min: -5.34  Med: 0.83 Max: 0.98
Current: 0.85
-5.34
0.98
Interest Coverage No Debt
NAS:BSTC's Interest Coverage is ranked higher than
99% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:BSTC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:BSTC' s Interest Coverage Range Over the Past 10 Years
Min: 80.45  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 4
Z-Score: 24.53
M-Score: -2.54
WACC vs ROIC
17.01%
122.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 64.37
NAS:BSTC's Operating margin (%) is ranked higher than
98% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NAS:BSTC: 64.37 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:BSTC' s Operating margin (%) Range Over the Past 10 Years
Min: -296.7  Med: 45.26 Max: 64.37
Current: 64.37
-296.7
64.37
Net-margin (%) 43.42
NAS:BSTC's Net-margin (%) is ranked higher than
96% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. NAS:BSTC: 43.42 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:BSTC' s Net-margin (%) Range Over the Past 10 Years
Min: -300.13  Med: 34.86 Max: 63.95
Current: 43.42
-300.13
63.95
ROE (%) 24.65
NAS:BSTC's ROE (%) is ranked higher than
94% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NAS:BSTC: 24.65 )
Ranked among companies with meaningful ROE (%) only.
NAS:BSTC' s ROE (%) Range Over the Past 10 Years
Min: -31.9  Med: 18.44 Max: 61.21
Current: 24.65
-31.9
61.21
ROA (%) 22.55
NAS:BSTC's ROA (%) is ranked higher than
97% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. NAS:BSTC: 22.55 )
Ranked among companies with meaningful ROA (%) only.
NAS:BSTC' s ROA (%) Range Over the Past 10 Years
Min: -156.91  Med: 19.63 Max: 53.14
Current: 22.55
-156.91
53.14
ROC (Joel Greenblatt) (%) 346.98
NAS:BSTC's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. NAS:BSTC: 346.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:BSTC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -406600  Med: 141.2 Max: 369.76
Current: 346.98
-406600
369.76
Revenue Growth (3Y)(%) 25.10
NAS:BSTC's Revenue Growth (3Y)(%) is ranked higher than
78% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. NAS:BSTC: 25.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:BSTC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -46.8  Med: 7.1 Max: 65.2
Current: 25.1
-46.8
65.2
EBITDA Growth (3Y)(%) 41.70
NAS:BSTC's EBITDA Growth (3Y)(%) is ranked higher than
88% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:BSTC: 41.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:BSTC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 7.6 Max: 157.7
Current: 41.7
0
157.7
EPS Growth (3Y)(%) 45.30
NAS:BSTC's EPS Growth (3Y)(%) is ranked higher than
90% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. NAS:BSTC: 45.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:BSTC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.1  Med: 2.3 Max: 79.6
Current: 45.3
-44.1
79.6
» NAS:BSTC's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

BSTC Guru Trades in Q3 2015

Chuck Royce 46,200 sh (unchged)
Jim Simons 192,700 sh (-6.22%)
» More
Q4 2015

BSTC Guru Trades in Q4 2015

Jim Simons 253,367 sh (+31.48%)
Chuck Royce 46,200 sh (unchged)
» More
Q1 2016

BSTC Guru Trades in Q1 2016

Chuck Royce 74,590 sh (+61.45%)
Jim Simons 249,200 sh (-1.64%)
» More
Q2 2016

BSTC Guru Trades in Q2 2016

Chuck Royce 95,100 sh (+27.50%)
Jim Simons 271,400 sh (+8.91%)
» More
» Details

Insider Trades

Latest Guru Trades with BSTC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:SPHDF, NAS:EDGE, NAS:CRIS, NAS:IMMU, NAS:FOMX, NAS:SYRS, NAS:PETX, NAS:ESPR, NAS:PRTK, NAS:SVA, NAS:CRVS, NAS:IDRA, NAS:OVAS, OTCPK:TYMI, NAS:MESO, NAS:PTI, NAS:MNKD, NAS:CGEN, NAS:BCRX, NAS:AKBA » details
BioSpecifics Technologies Corp is a biopharmaceutical company, which is engaged in the development of an injectable collagenase for multiple indications.

BioSpecifics Technologies Corp was incorporated in Delaware in 1990. It is a biopharmaceutical company engaged in the development of an injectable collagenase for multiple indications. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase for indications in development. Auxilium is currently selling XIAFLEX in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease. In December 2013, FDA approved Auxilium's supplemental Biologics License Application ('sBLA') for XIAFLEX for the treatment of Peyronie's disease. The Company and its licensees face competition from larger pharmaceutical companies, specialty pharmaceutical companies and biotechnology firms, universities and other research institutions and government agencies that are developing and commercializing pharmaceutical products. As a biopharmaceutical company, the Company is subject to a large body of legal and regulatory requirements.

Ratios

vs
industry
vs
history
P/E(ttm) 31.47
BSTC's P/E(ttm) is ranked lower than
53% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 29.00 vs. BSTC: 31.47 )
Ranked among companies with meaningful P/E(ttm) only.
BSTC' s P/E(ttm) Range Over the Past 10 Years
Min: 15.05  Med: 35.51 Max: 88.33
Current: 31.47
15.05
88.33
Forward P/E 26.95
BSTC's Forward P/E is ranked lower than
67% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 19.65 vs. BSTC: 26.95 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 31.47
BSTC's PE(NRI) is ranked lower than
52% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BSTC: 31.47 )
Ranked among companies with meaningful PE(NRI) only.
BSTC' s PE(NRI) Range Over the Past 10 Years
Min: 15.05  Med: 35.37 Max: 88.33
Current: 31.47
15.05
88.33
P/B 6.60
BSTC's P/B is ranked lower than
70% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. BSTC: 6.60 )
Ranked among companies with meaningful P/B only.
BSTC' s P/B Range Over the Past 10 Years
Min: 4.64  Med: 7.82 Max: 600
Current: 6.6
4.64
600
P/S 13.56
BSTC's P/S is ranked lower than
51% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. BSTC: 13.56 )
Ranked among companies with meaningful P/S only.
BSTC' s P/S Range Over the Past 10 Years
Min: 2.54  Med: 14.08 Max: 74.47
Current: 13.56
2.54
74.47
POCF 21.95
BSTC's POCF is ranked higher than
53% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 23.11 vs. BSTC: 21.95 )
Ranked among companies with meaningful POCF only.
BSTC' s POCF Range Over the Past 10 Years
Min: 1.06  Med: 45.68 Max: 3552.86
Current: 21.95
1.06
3552.86
EV-to-EBIT 17.60
BSTC's EV-to-EBIT is ranked higher than
61% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 23.97 vs. BSTC: 17.60 )
Ranked among companies with meaningful EV-to-EBIT only.
BSTC' s EV-to-EBIT Range Over the Past 10 Years
Min: -128.8  Med: 15.7 Max: 63.9
Current: 17.6
-128.8
63.9
EV-to-EBITDA 16.17
BSTC's EV-to-EBITDA is ranked higher than
58% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. BSTC: 16.17 )
Ranked among companies with meaningful EV-to-EBITDA only.
BSTC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -132.2  Med: 15.2 Max: 62.9
Current: 16.17
-132.2
62.9
Shiller P/E 125.77
BSTC's Shiller P/E is ranked lower than
80% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 47.58 vs. BSTC: 125.77 )
Ranked among companies with meaningful Shiller P/E only.
BSTC' s Shiller P/E Range Over the Past 10 Years
Min: 98.76  Med: 231.7 Max: 1349
Current: 125.77
98.76
1349
Current Ratio 29.24
BSTC's Current Ratio is ranked higher than
96% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. BSTC: 29.24 )
Ranked among companies with meaningful Current Ratio only.
BSTC' s Current Ratio Range Over the Past 10 Years
Min: 0.43  Med: 5.93 Max: 48.18
Current: 29.24
0.43
48.18
Quick Ratio 29.24
BSTC's Quick Ratio is ranked higher than
96% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. BSTC: 29.24 )
Ranked among companies with meaningful Quick Ratio only.
BSTC' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 5.28 Max: 48.18
Current: 29.24
0.41
48.18
Days Sales Outstanding 62.03
BSTC's Days Sales Outstanding is ranked higher than
50% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. BSTC: 62.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSTC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.95  Med: 115.13 Max: 299.91
Current: 62.03
8.95
299.91

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.90
BSTC's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. BSTC: -2.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BSTC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6  Med: -1.8 Max: 2.7
Current: -2.9
-6
2.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.45
BSTC's Price/Net Cash is ranked lower than
61% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 6.18 vs. BSTC: 9.45 )
Ranked among companies with meaningful Price/Net Cash only.
BSTC' s Price/Net Cash Range Over the Past 10 Years
Min: 2.85  Med: 11.79 Max: 65.22
Current: 9.45
2.85
65.22
Price/Net Current Asset Value 7.86
BSTC's Price/Net Current Asset Value is ranked lower than
60% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. BSTC: 7.86 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BSTC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.05  Med: 7.27 Max: 40.52
Current: 7.86
1.05
40.52
Price/Tangible Book 6.62
BSTC's Price/Tangible Book is ranked lower than
62% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. BSTC: 6.62 )
Ranked among companies with meaningful Price/Tangible Book only.
BSTC' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.59  Med: 3.3 Max: 485.71
Current: 6.62
0.59
485.71
Price/Projected FCF 8.54
BSTC's Price/Projected FCF is ranked lower than
72% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.64 vs. BSTC: 8.54 )
Ranked among companies with meaningful Price/Projected FCF only.
BSTC' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.66  Med: 8.84 Max: 82.08
Current: 8.54
0.66
82.08
Price/Median PS Value 0.96
BSTC's Price/Median PS Value is ranked higher than
57% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. BSTC: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
BSTC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.04  Med: 0.53 Max: 4.28
Current: 0.96
0.04
4.28
Price/Peter Lynch Fair Value 1.26
BSTC's Price/Peter Lynch Fair Value is ranked higher than
66% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 1.61 vs. BSTC: 1.26 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BSTC' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.61  Med: 1.09 Max: 2.67
Current: 1.26
0.61
2.67
Price/Graham Number 3.04
BSTC's Price/Graham Number is ranked lower than
52% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 2.74 vs. BSTC: 3.04 )
Ranked among companies with meaningful Price/Graham Number only.
BSTC' s Price/Graham Number Range Over the Past 10 Years
Min: 0.87  Med: 2.7 Max: 8.99
Current: 3.04
0.87
8.99
Earnings Yield (Greenblatt) (%) 5.68
BSTC's Earnings Yield (Greenblatt) (%) is ranked higher than
90% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. BSTC: 5.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BSTC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.6  Med: 4.1 Max: 1356.6
Current: 5.68
1.6
1356.6
Forward Rate of Return (Yacktman) (%) 35.23
BSTC's Forward Rate of Return (Yacktman) (%) is ranked higher than
85% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 14.98 vs. BSTC: 35.23 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BSTC' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -20.5  Med: 0.1 Max: 35.23
Current: 35.23
-20.5
35.23

More Statistics

Revenue (TTM) (Mil) $25.18
EPS (TTM) $ 1.49
Beta2.05
Short Percentage of Float2.86%
52-Week Range $30.70 - 63.20
Shares Outstanding (Mil)7.01

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 26 29
EPS ($) 1.53 1.71
EPS w/o NRI ($) 1.53 1.71
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:BSTC

Headlines

Articles On GuruFocus.com
BioSpecifics Technologies Corp. Reports Operating Results (10-Q) Aug 09 2010 
BioSpecifics Technologies Corp. Reports Operating Results (10-Q) Aug 13 2009 
BioSpecifics Technologies Corp. Reports Operating Results for Fiscal Quarter Ended on 2008-03-31 Jan 13 2009 
BioSpecifics Technologies Corp. Reports Operating Results for Fiscal Quarter Ended on 2008-06-30 Jan 13 2009 
BioSpecifics Technologies Corp. Reports Operating Results for Fiscal Quarter Ended on 2008-09-30 Jan 13 2009 

More From Other Websites
PAREXEL International (PRXL) Set to Acquire ExecuPharm Sep 27 2016
BioSpecifics Technologies (BSTC) Catches Eye: Stock Up 5.2% Sep 21 2016
Can The Uptrend Continue for BioSpecifics Technologies (BSTC)? Sep 20 2016
BioSpecifics Technologies Corp. to Present at Two Upcoming September Conferences Sep 02 2016
What Makes Collegium Pharmaceutical (COLL) a Strong Sell? Aug 30 2016
ETF’s with exposure to Biospecifics Technologies Corp. : August 23, 2016 Aug 23 2016
New Strong Buy Stocks for August 22nd Aug 22 2016
BIOSPECIFICS TECHNOLOGIES CORP Financials Aug 19 2016
Catalyst Pharmaceuticals (CPRX) Looks Good: Stock Up 6.3% Aug 18 2016
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... Aug 15 2016
Biospecifics Technologies Corp. :BSTC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12,... Aug 12 2016
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 10 2016
BioSpecifics posts 2Q profit Aug 09 2016
BioSpecifics posts 2Q profit Aug 09 2016
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 10-Q, Quarterly Report Aug 09 2016
BioSpecifics Technologies Corp. Reports Second Quarter 2016 Financial Results Aug 09 2016
BioSpecifics Technologies Corp. Reports Second Quarter 2016 Financial Results Aug 09 2016
Q2 2016 Biospecifics Technologies Corp Earnings Release - Before Market Open Aug 09 2016
BioSpecifics Technologies Corp. to Report Second Quarter 2016 Financial Results on Tuesday, August... Aug 02 2016
BioSpecifics Technologies Corp. to Report Second Quarter 2016 Financial Results on Tuesday, August... Aug 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)